360 related articles for article (PubMed ID: 36675310)
41. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
42. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
Uszyński M; Perlik M; Uszyński W; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
[TBL] [Abstract][Full Text] [Related]
43. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
Pluskota E; Soloviev DA; Plow EF
Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
45. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.
Connolly BM; Choi EY; Gårdsvoll H; Bey AL; Currie BM; Chavakis T; Liu S; Molinolo A; Ploug M; Leppla SH; Bugge TH
Blood; 2010 Sep; 116(9):1593-603. PubMed ID: 20466854
[TBL] [Abstract][Full Text] [Related]
46. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
[TBL] [Abstract][Full Text] [Related]
47. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
48. Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection.
Gueler F; Rong S; Mengel M; Park JK; Kiyan J; Kirsch T; Dumler I; Haller H; Shushakova N
J Immunol; 2008 Jul; 181(2):1179-89. PubMed ID: 18606671
[TBL] [Abstract][Full Text] [Related]
49. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
50. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693
[TBL] [Abstract][Full Text] [Related]
51. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
52. Urokinase and its receptors in chronic kidney disease.
Zhang G; Eddy AA
Front Biosci; 2008 May; 13():5462-78. PubMed ID: 18508599
[TBL] [Abstract][Full Text] [Related]
53. Expression of urokinase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin.
Iwamoto J; Takahashi K; Mizokami Y; Otsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokoube K; Matsuoka T
Dig Dis Sci; 2003 Dec; 48(12):2247-56. PubMed ID: 14714609
[TBL] [Abstract][Full Text] [Related]
54. E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects.
Sharma S; Watanabe T; Nishimoto T; Takihara T; Mlakar L; Nguyen XX; Sanderson M; Su Y; Chambers RA; Feghali-Bostwick C
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935642
[TBL] [Abstract][Full Text] [Related]
55. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Akdoğan Ö; Atak Yücel A; Gök Sargin Z; Sönmez C; Esendağli Yilmaz G; Özenirler S
J Clin Exp Hepatol; 2019; 9(1):29-33. PubMed ID: 30765936
[TBL] [Abstract][Full Text] [Related]
57. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
58. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
59. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1.
Bhandary YP; Shetty SK; Marudamuthu AS; Ji HL; Neuenschwander PF; Boggaram V; Morris GF; Fu J; Idell S; Shetty S
Am J Pathol; 2013 Jul; 183(1):131-43. PubMed ID: 23665346
[TBL] [Abstract][Full Text] [Related]
60. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
